Zoltan Laboratories LLC (ZL) is developing a drug to
treat and protect the normal functions of healthy
organs in patients who battle both diabetes and cancer.
About 10-15% of cancer patients are also diabetic, and
treatment of this patient group is very difficult.
ZL's drug will enhance the efficacy of both diabetic
and cancer treatments as well as ensure a better quality
of life for these patients.
Without treatment, the growing tumor as well as inflammation and ensuing diabetes damages key organs in diabetic cancer patients (Scheme 1).
Treatment with ZL's drug inactivates a key inflammatory mediator resulting in the normalization of body weight and blood glucose as well as reduced damage of normal organs (scheme2). In addition, the drug directly enhances survival of normal cells while reducing the growth of tumors. As a combination of these effects, ZL's drug enhances cancer therapy while reduces the side effects including cachexia (body weight loss) and allows safer use of diabetes therapies as well.
Without treatment, the growing tumor as well as inflammation and ensuing diabetes damages key organs in diabetic cancer patients (Scheme 1).
Treatment with ZL's drug inactivates a key inflammatory mediator resulting in the normalization of body weight and blood glucose as well as reduced damage of normal organs (scheme2). In addition, the drug directly enhances survival of normal cells while reducing the growth of tumors. As a combination of these effects, ZL's drug enhances cancer therapy while reduces the side effects including cachexia (body weight loss) and allows safer use of diabetes therapies as well.